AIS treatment in the general, non-COVID-19 population primarily includes blood pressure control, anticoagulation, long-term dual antiplatelet agents and statin therapy, potential thrombolysis using recombinant tissue plasminogen activator (rt-PA; i.e., alteplase) and mechanical thrombectomy depending on the case and if the patient is within the therapeutic window of 3 to 4.5 h or within 6 h, respectively [3,12,37,38]. This evidence concerns the gene PLAT and COVID-19.